AVITA Medical Inc’s recent filing unveils that its Director McNamara Robert acquired Company’s shares for reported $91300.0 on Mar 06 ’25. In the deal valued at $8.30 per share,11,000 shares were bought. As a result of this transaction, McNamara Robert now holds 56,749 shares worth roughly $0.41 million.
Then, McNamara Robert bought 10,000 shares, generating $100,900 in total proceeds. Upon buying the shares at $10.09, the Director now owns 45,749 shares.
Before that, O’Toole David D bought 1,000 shares. AVITA Medical Inc shares valued at $9,900 were divested by the CFO at a price of $9.90 per share. As a result of the transaction, O’Toole David D now holds 25,734 shares, worth roughly $0.19 million.
D. Boral Capital initiated its AVITA Medical Inc [RCEL] rating to a Buy in a research note published on December 24, 2024; the price target was $25. A number of analysts have revised their coverage, including BTIG Research’s analysts, who decreased its forecast for the stock in mid April from “a Buy” to “a Neutral”. Cantor Fitzgerald began covering RCEL with “an Overweight” recommendation on June 27, 2023. Piper Sandler started covering the stock on March 02, 2021. It rated RCEL as “an Overweight”.
Price Performance Review of RCEL
On Monday, AVITA Medical Inc [NASDAQ:RCEL] saw its stock jump 4.02% to $7.25. Over the last five days, the stock has lost -21.28%. AVITA Medical Inc shares have fallen nearly -43.36% since the year began. Nevertheless, the stocks have fallen -19.08% over the past one year. While a 52-week high of $14.16 was reached on 01/07/25, a 52-week low of $6.60 was recorded on 05/09/25. SMA at 50 days reached $8.85, while 200 days put it at $10.09.
Levels Of Support And Resistance For RCEL Stock
The 24-hour chart illustrates a support level at 6.89, which if violated will result in even more drops to 6.52. On the upside, there is a resistance level at 7.51. A further resistance level may holdings at 7.76. The Relative Strength Index (RSI) on the 14-day chart is 31.99, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.41, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.38%. Stochastics %K at 20.63% indicates the stock is a holding.
The most recent change occurred on August 27, 2020 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $42 price target.
